Today’s AI Top Pick: ADMA

ADMA Biologics is the cleanest bullish setup in this pool: it stacks a top-tier fundamental profile with a deeply reset tape and the highest expected return in the group (82.9%). The valuation is genuinely cheap for a growing specialty biologic — PE 13.56, fwdPE 10.12, PEG 0.45 — while profitability is elite (ROE 41.9%, profitMargin 32.98%, operMargin 42.26%, grossMargin 64.67%). Sell-side is aligned (recom 1.33 = strong buy) with an aggressive 95.5% targetUpsidePct, and bullish_prob is a full 1.0 with the max fundamental_score of 8. The tape confirms the entry rather than fights it. RSI sits at 53.9 — dead-center of the 40–65 window, so you're not chasing a blowoff. Crucially, ADMA is down 47.6% YTD and 46.4% over the trailing year, meaning position in range is depressed rather than extended — exactly what rule #2 asks for (drawdown acceptable, don't chase the top). That is a much more attractive risk/reward than names like NFLX (RSI 62.6), EPAM (RSI 64.65, targetUpside only 8.5%), or LBRDA whose 4h is at 100% of its 21-bar range (textbook chase). LBRDA has the flashiest forecast (1wk fc_long +121.79%, 1d fc_mid +49.52%) and is the only name with a full tf block, but its fundamentals are structurally broken: null PE/PS, ROE −66.6%, salesYoY −100%, null gross/operating margin — the salesYoY print reflects a corporate restructuring (Comcast/NBCUniversal spin news 6/29) and Simply Wall St flagged a 'softer Q1 2026' bull case. The 4h being pinned at the top of range means any pullback there is your entry, not today. ADMA gives you the same 'reliable bullish' screen pass with real earnings behind it. Why today, not later: RSI 53.9 with a −47% YTD drawdown, PEG 0.45 and fwdPE 10.12 means the risk of paying up here is minimal, and the screen (bullish_prob 1, recom 1.33, fundamental_score 8) is already firing. Waiting risks losing the reset — the setup is 'washed out but not broken' and those windows tend to close quickly once institutional flows (instOwn already 90.12%) shift back.